Verus Capital Partners LLC Sells 3,821 Shares of AbbVie Inc. $ABBV

Verus Capital Partners LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 6.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 53,144 shares of the company’s stock after selling 3,821 shares during the quarter. AbbVie makes up about 0.8% of Verus Capital Partners LLC’s holdings, making the stock its 29th largest holding. Verus Capital Partners LLC’s holdings in AbbVie were worth $11,558,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after buying an additional 3,032,438 shares in the last quarter. State Street Corp boosted its position in AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC boosted its position in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after acquiring an additional 356,394 shares during the period. Finally, Norges Bank purchased a new position in shares of AbbVie in the 4th quarter valued at $5,865,055,000. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Bank of America lifted their target price on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. UBS Group boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Finally, Morgan Stanley raised their price target on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $269.29.

AbbVie Trading Down 2.4%

Shares of ABBV stock opened at $251.33 on Friday. AbbVie Inc. has a 12-month low of $187.62 and a 12-month high of $267.47. The business’s fifty day simple moving average is $239.10 and its 200-day simple moving average is $224.05. The company has a market cap of $444.05 billion, a PE ratio of 123.81, a PEG ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.78 billion. During the same quarter last year, the firm earned $2.97 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts forecast that AbbVie Inc. will post 14.14 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.